Roche announces an increase in group sales of 7% for 2018



[ad_1]

The sales figure of its diagnostics division grew by 7% in 2018, and its pharmaceutical unit experienced the same growth. He said the main drivers of growth were the new drug Ocrevus Multiple Sclerosis and the anti-cancer drugs Perjeta, Tecentriq, Alecensa, as well as the new Hemlibra hemophilia drug.

Schwan said the new drugs accounted for 90% of the company 's sales growth in 2018 and qualified the launch of Ocrevus as "most successful" in Roche' s history.

The United States, which has been subject to increased drug price surveillance in recent years, is a key market for Roche's pharmaceutical sector. Schwan told CNBC's Julianna Tatelbaum that "everything depends on the value you offer to patients".

"And with our strategy focused on research and innovation, I think we are well positioned because we can bring this real benefit to patients." And my experience is that, especially in the United States, the company is also ready to reward this type of innovation I am therefore confident that the United States will remain a very attractive market, "he said.

[ad_2]
Source link